NEW YORK (GenomeWeb) – As it seeks to build out its non-invasive prenatal testing business, Natera is set to move into the cancer diagnostics space.

The San Carlos, Calif.-based firm, probably best known for its Panorama NIPT launched in early 2013 for detecting fetal aneuploidies, is in the midst of preparing that test for use in the lower-risk pregnancy population. Like other NIPTs, Panorama has largely been used for higher-risk populations.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.